[go: up one dir, main page]

MX2022009898A - Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo. - Google Patents

Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo.

Info

Publication number
MX2022009898A
MX2022009898A MX2022009898A MX2022009898A MX2022009898A MX 2022009898 A MX2022009898 A MX 2022009898A MX 2022009898 A MX2022009898 A MX 2022009898A MX 2022009898 A MX2022009898 A MX 2022009898A MX 2022009898 A MX2022009898 A MX 2022009898A
Authority
MX
Mexico
Prior art keywords
compound
dihydronaphthyridinone
preparation
method therefor
medical use
Prior art date
Application number
MX2022009898A
Other languages
English (en)
Inventor
Xiaoming Xu
Fusheng Zhou
Xin Li
Leitao Zhang
Lili Tang
Jiong Lan
Original Assignee
Genfleet Therapeutics Shanghai Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genfleet Therapeutics Shanghai Inc filed Critical Genfleet Therapeutics Shanghai Inc
Publication of MX2022009898A publication Critical patent/MX2022009898A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Se proporciona un compuesto de dihidronaftiridinona como se muestra en la fórmula (I), el compuesto que tiene un efecto inhibidor selectivo sobre RIPK1, y una sal, un estereoisómero, un solvato o un profármaco farmacéuticamente aceptable del mismo. Además, se proporciona una composición farmacéutica que contiene el compuesto y el uso del mismo en la preparación de un fármaco para tratar enfermedades o afecciones relacionadas con RIPK1. (ver Fórmula).
MX2022009898A 2020-02-13 2021-02-09 Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo. MX2022009898A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010090252 2020-02-13
CN202110070075 2021-01-19
PCT/CN2021/076160 WO2021160109A1 (zh) 2020-02-13 2021-02-09 二氢萘啶酮类化合物，其制法与医药上的用途

Publications (1)

Publication Number Publication Date
MX2022009898A true MX2022009898A (es) 2022-08-25

Family

ID=77291388

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022009898A MX2022009898A (es) 2020-02-13 2021-02-09 Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo.

Country Status (12)

Country Link
US (1) US20230139111A1 (es)
EP (1) EP4105216A4 (es)
JP (1) JP7441477B2 (es)
KR (1) KR20220141321A (es)
CN (1) CN115135648B (es)
AU (1) AU2021219832B9 (es)
BR (1) BR112022016124A2 (es)
CA (1) CA3167847A1 (es)
MX (1) MX2022009898A (es)
TW (1) TWI779487B (es)
WO (1) WO2021160109A1 (es)
ZA (1) ZA202209741B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI824626B (zh) * 2021-08-02 2023-12-01 大陸商勁方醫藥科技(上海)有限公司 Ripk1抑制劑的晶型及其酸式鹽和其酸式鹽的晶型
US20250197390A1 (en) 2022-03-16 2025-06-19 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Fused heterocyclic compound, and preparation method therefor and medical use thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009296820B2 (en) * 2008-09-26 2014-03-20 Merck Sharp & Dohme Llc Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010052222A1 (en) * 2008-11-07 2010-05-14 Evotec Neurosciences Gmbh (dihydro)naphthyridinone derivatives as histamine h3 receptor antagonists
WO2011076734A1 (en) * 2009-12-21 2011-06-30 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases
WO2011076732A1 (en) * 2009-12-21 2011-06-30 Euroscreen S.A. Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders
RU2012112128A (ru) * 2012-03-29 2013-10-10 Холин Максим Николаевич ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
MX2016009135A (es) * 2014-01-14 2016-10-05 Millennium Pharm Inc Heteroarilos y usos de estos.
HUE057801T2 (hu) * 2017-02-13 2022-06-28 Bristol Myers Squibb Co Aminotriazolopiridinek mint kináz inhibitorok
WO2018157277A1 (en) * 2017-02-28 2018-09-07 Eli Lilly And Company Isoquinolin and naphthydrin compounds
US20220177462A1 (en) * 2019-03-22 2022-06-09 Genfleet Therapeutics (Shanghai) Inc. Substituted heterocyclic amide compound and preparation method therefor and pharmaceutical use thereof

Also Published As

Publication number Publication date
TW202140476A (zh) 2021-11-01
CA3167847A1 (en) 2021-08-19
ZA202209741B (en) 2023-04-26
JP2023513825A (ja) 2023-04-03
AU2021219832A1 (en) 2022-09-29
EP4105216A1 (en) 2022-12-21
CN115135648B (zh) 2024-02-09
CN115135648A (zh) 2022-09-30
US20230139111A1 (en) 2023-05-04
KR20220141321A (ko) 2022-10-19
AU2021219832B9 (en) 2024-02-15
BR112022016124A2 (pt) 2022-10-25
AU2021219832B2 (en) 2024-01-25
WO2021160109A1 (zh) 2021-08-19
TWI779487B (zh) 2022-10-01
JP7441477B2 (ja) 2024-03-01
EP4105216A4 (en) 2024-02-28

Similar Documents

Publication Publication Date Title
ZA202309638B (en) Pyrimidine-fused cyclic compound, preparation method therefor and use thereof
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
WO2021147236A9 (zh) 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用
MY210283A (en) 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
CA3057882A1 (en) Substituted dihydro-spiro-napthalene-oxa derivatives and pharmaceutical compositions thereof useful as inhibitors of mcl-1 protein
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
MX2022004450A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1.
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
ZA202400988B (en) Aak1 inhibitor and use thereof
MX2021007247A (es) Derivados de rapamicina.
PH12022550790A1 (en) Oral complement factor d inhibitors
PH12021550713A1 (en) Medicament for the treatment of chronic cough
PH12021551985A1 (en) Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia
TN2022000255A1 (en) Pyrrolopyrimidine amines as complement inhibitors
PH12021552513A1 (en) Pyrrole compounds
PH12022552727A1 (en) COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2a AND THEIR METHODS OF USE
MX2021012491A (es) Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
PH12022550794A1 (en) Oral complement factor d inhibitors
MX2024013020A (es) Compuestos de heteroarilo para el tratamiento del dolor
MX2022009898A (es) Compuesto de dihidronaftiridinona y metodo de preparacion del mismo y uso medico del mismo.
MX2023005913A (es) Derivados de bencenosulfonamida y usos de los mismos.
MX2022012001A (es) Tratamiento preventivo de la migra?a.
MX2022006052A (es) Inhibidores de la caspasa 6 y usos de los mismos.